Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN2420 add-on to somatostatin analogs in adults with acromegaly
2025-521243-20-00Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Sep 2025
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in acromegaly comparing ALXN2420 + long-acting somatostatin analog with Placebo + long-acting somatostatin analog (2 arms). Primary endpoint: Percentage change from baseline in serum IGF-1 level at Week 15. Started Sep 2025; status: completed.
02
Drugs
AZP-3813
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2025-521243-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521243-20-00.